Literature DB >> 24444660

Advanced cardiac amyloidosis associated with normal interventricular septal thickness: an uncommon presentation of infiltrative cardiomyopathy.

Rahul Suresh1, Martha Grogan2, Joseph J Maleszewski3, Patricia A Pellikka2, Mazen Hanna4, Angela Dispenzieri5, Naveen L Pereira6.   

Abstract

BACKGROUND: Increased interventricular septal (IVS) thickness on echocardiography is a diagnostic criterion for cardiac amyloidosis and classically precedes decrement in left ventricular ejection fraction (LVEF). The investigators describe patients with histologically confirmed cardiac amyloidosis who had significant myocardial dysfunction (LVEF ≤ 40%) despite having normal IVS thickness.
METHODS: All patients with systemic amyloidosis and LVEFs ≤ 40% were analyzed to identify the prevalence of normal IVS thickness. Patients with known histories of cardiomyopathy or coronary artery disease were excluded. Histologic evaluation of tissue included assessment of amyloid burden and average myocyte diameter.
RESULTS: There were 255 patients with amyloidosis with LVEFs ≤ 40%, of whom seven (3%) had normal IVS thickness and histologic confirmation of cardiac involvement. Of these, six had immunoglobulin light chain amyloidosis, and one had senile amyloidosis. A majority of patients (86%) presented with new-onset cardiac dysfunction associated with edema and/or dyspnea. Electrocardiographic findings included low voltage (43%) and a pseudoinfarct pattern (29%). The 1-year survival from initial tissue diagnosis in the cohort with normal IVS thickness was similar to matched patients with amyloidosis with increased IVS thickness and LVEF ≤ 40% (21% vs 18%, respectively, P = .32). Myocardial tissue amyloid burden and average myocyte diameter were significantly reduced in cases compared with controls.
CONCLUSIONS: Cardiac amyloidosis can uncommonly present with normal IVS thickness despite significant myocardial dysfunction. The prognosis of these patients is as poor as those with increased IVS thickness. Amyloidosis should be considered in the differential diagnosis of patients with cardiomyopathy and reduced LVEFs despite normal IVS thickness.
Copyright © 2014 American Society of Echocardiography. Published by Mosby, Inc. All rights reserved.

Entities:  

Keywords:  Amyloid; Cardiomyopathy; Diagnosis; Echocardiography; Heart failure

Mesh:

Year:  2014        PMID: 24444660      PMCID: PMC3972307          DOI: 10.1016/j.echo.2013.12.010

Source DB:  PubMed          Journal:  J Am Soc Echocardiogr        ISSN: 0894-7317            Impact factor:   5.251


  39 in total

1.  Therapeutic advances demand accurate typing of amyloid deposits.

Authors:  E Anesi; G Palladini; V Perfetti; E Arbustini; L Obici; G Merlini
Journal:  Am J Med       Date:  2001-08-15       Impact factor: 4.965

2.  ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography).

Authors:  Melvin D Cheitlin; William F Armstrong; Gerard P Aurigemma; George A Beller; Fredrick Z Bierman; Jack L Davis; Pamela S Douglas; David P Faxon; Linda D Gillam; Thomas R Kimball; William G Kussmaul; Alan S Pearlman; John T Philbrick; Harry Rakowski; Daniel M Thys; Elliott M Antman; Sidney C Smith; Joseph S Alpert; Gabriel Gregoratos; Jeffrey L Anderson; Loren F Hiratzka; Sharon Ann Hunt; Valentin Fuster; Alice K Jacobs; Raymond J Gibbons; Richard O Russell
Journal:  Circulation       Date:  2003-09-02       Impact factor: 29.690

3.  The diagnosis and typing of cardiac amyloidosis.

Authors:  Carl J O'Hara; Rodney H Falk
Journal:  Amyloid       Date:  2003-06       Impact factor: 7.141

4.  Systemic amyloidosis presenting with angina pectoris.

Authors:  J Al Suwaidi; J L Velianou; M A Gertz; R O Cannon; S T Higano; D R Holmes; A Lerman
Journal:  Ann Intern Med       Date:  1999-12-07       Impact factor: 25.391

5.  Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts.

Authors:  R Liao; M Jain; P Teller; L H Connors; S Ngoy; M Skinner; R H Falk; C S Apstein
Journal:  Circulation       Date:  2001-10-02       Impact factor: 29.690

6.  Quantitative analysis of serum free light chains. A new marker for the diagnostic evaluation of primary systemic amyloidosis.

Authors:  Roshini S Abraham; Jerry A Katzmann; Raynell J Clark; A R Bradwell; Robert A Kyle; Morie A Gertz
Journal:  Am J Clin Pathol       Date:  2003-02       Impact factor: 2.493

7.  Electron and immuno-electron microscopy of abdominal fat identifies and characterizes amyloid fibrils in suspected cardiac amyloidosis.

Authors:  Eloisa Arbustini; Laura Verga; Monica Concardi; Giovanni Palladini; Laura Obici; Giampaolo Merlini
Journal:  Amyloid       Date:  2002-06       Impact factor: 7.141

8.  Relationship between monoclonal gammopathy and cardiac amyloid type.

Authors:  Joseph J Maleszewski; David L Murray; Angela Dispenzieri; Martha Grogan; Naveen L Pereira; Sarah M Jenkins; Daniel P Judge; Patrizio Caturegli; Julie A Vrana; Jason D Theis; Ahmet Dogan; Marc K Halushka
Journal:  Cardiovasc Pathol       Date:  2012-10-24       Impact factor: 2.185

9.  Noninvasive diagnosis of biopsy-proven cardiac amyloidosis.

Authors:  Joseph E Rahman; Emelie F Helou; Ramona Gelzer-Bell; Richard E Thompson; Chih Kuo; E Rene Rodriguez; Joshua M Hare; Kenneth L Baughman; Edward K Kasper
Journal:  J Am Coll Cardiol       Date:  2004-02-04       Impact factor: 24.094

10.  Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress.

Authors:  Daniel A Brenner; Mohit Jain; David R Pimentel; Bo Wang; Lawreen H Connors; Martha Skinner; Carl S Apstein; Ronglih Liao
Journal:  Circ Res       Date:  2004-03-25       Impact factor: 17.367

View more
  9 in total

Review 1.  Pathophysiology and treatment of cardiac amyloidosis.

Authors:  Morie A Gertz; Angela Dispenzieri; Taimur Sher
Journal:  Nat Rev Cardiol       Date:  2014-10-14       Impact factor: 32.419

2.  Myocardial strain pattern in patients with cardiac amyloidosis secondary to multiple myeloma: a cardiac MRI feature tracking study.

Authors:  Sabha Bhatti; Srikanth Vallurupalli; Stephanie Ambach; Adam Magier; Evan Watts; Vien Truong; Abdul Hakeem; Wojciech Mazur
Journal:  Int J Cardiovasc Imaging       Date:  2016-10-14       Impact factor: 2.357

Review 3.  Recent advances in the noninvasive strategies of cardiac amyloidosis.

Authors:  Lei Zhao; Quan Fang
Journal:  Heart Fail Rev       Date:  2016-11       Impact factor: 4.214

Review 4.  Advances in the diagnosis and treatment of transthyretin amyloidosis with cardiac involvement.

Authors:  Angelos G Rigopoulos; Muhammad Ali; Elena Abate; Abdel-Rahman Torky; Marios Matiakis; Mammad Mammadov; Hannes Melnyk; Alexander Vogt; Renato de Vecchis; Boris Bigalke; Walter Wohlgemuth; Sophie Mavrogeni; Michel Noutsias
Journal:  Heart Fail Rev       Date:  2019-07       Impact factor: 4.214

5.  Epigenomic Profiles of African-American Transthyretin Val122Ile Carriers Reveals Putatively Dysregulated Amyloid Mechanisms.

Authors:  Gita A Pathak; Frank R Wendt; Antonella De Lillo; Yaira Z Nunez; Aranyak Goswami; Flavio De Angelis; Maria Fuciarelli; Henry R Kranzler; Joel Gelernter; Renato Polimanti
Journal:  Circ Genom Precis Med       Date:  2021-01-11

Review 6.  Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response.

Authors:  Martha Grogan; Angela Dispenzieri; Morie A Gertz
Journal:  Heart       Date:  2017-04-29       Impact factor: 5.994

Review 7.  Physiology, Diagnosis and Treatment of Cardiac Light Chain Amyloidosis.

Authors:  Agnieszka Stelmach-Gołdyś; Monika Zaborek-Łyczba; Jakub Łyczba; Bartosz Garus; Marcin Pasiarski; Paulina Mertowska; Paulina Małkowska; Rafał Hrynkiewicz; Paulina Niedźwiedzka-Rystwej; Ewelina Grywalska
Journal:  J Clin Med       Date:  2022-02-09       Impact factor: 4.241

8.  Slip-Ups in the Diagnosis of Cardiac Amyloidosis: A Case Fatality in Point.

Authors:  Marissa Hobocan; Ayesha Shaik; Amjad Saad; Oisharya Dasgupta; Abhishek Jaiswal
Journal:  Cureus       Date:  2022-02-21

9.  3.0T cardiac magnetic resonance quantification of native T1 and myocardial extracellular volume for the diagnosis of late gadolinium enhancement-negative cardiac amyloidosis.

Authors:  Yumeng Liu; Jingfen Zhu; Meng Chen; Lingjie Wang; Mo Zhu; Zhen Weng; Chunhong Hu
Journal:  Ann Transl Med       Date:  2022-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.